ArticleScientific reports2025
Opioid quantification via microsampling techniques to assess opioid use in human laboratory studies.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Despite progress in neurobiological studies with human subjects, sample availability remains a challenge. Urine samples, widely used for screening, suffer from false-positive results due to immunoassay cross-reactivity. Serum, used for confirmatory testing, offers advantages but faces limitations due to blood collection. Microsamples, with a working volume less than 50 μL, present an ideal strategy for robust quantitative data collection in investigations and human laboratory studies. We developed, validated, and automated a serum-based LC-MS/MS assay for accurate quantification of six opioids using only 20 μL of patient samples. Our method, applied in a clinical trial with patients with opioid use disorder (N = 20) receiving intranasal oxytocin, or placebo, for one week in addition to opioid agonist therapy (buprenorphine or methadone). We quantified six different opioids, undetected by urine strip tests, that were used by patients during the treatment phase. Our high-throughput, automated approach surpasses existing methods in literature, enhancing efficiency in multi-matrix studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.